Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: Results from the European Forsteo Observational Study

Joint Bone Spine

Volumn 81, Issue 1, 2014, Pages 69-75

  Rajzbaum, Gerald ^a   Grados, Franck ^b   Evans, David ^c   Liu Leage, Soyi ^c   Petto, Helmut ^d   Augendre Ferrante, Béatrice ^c  

^a SAINT JOSEPH HOSPITAL   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c Lilly France ^*  (France)

^d Lilly Research Laboratories   (Austria)

Author keywords

Back pain; Fractures; Osteoporosis; Quality of life; Teriparatide

Indexed keywords

ALENDRONIC ACID; CALCITONIN; ESTROGEN; ETIDRONIC ACID; PARATHYROID HORMONE[1-34]; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; CALCIUM; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BACKACHE; FEMALE; FOLLOW UP; FOREARM FRACTURE; FRANCE; HEALTH CARE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OBSERVATIONAL STUDY; OSTEOPOROSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; REIMBURSEMENT; RHEUMATOLOGY; SPINE FRACTURE; TREATMENT DURATION; VERY ELDERLY; WRIST FRACTURE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; FRACTURE; HUMERUS FRACTURE; LEG FRACTURE; PELVIS FRACTURE; POSTMENOPAUSE; PRESCRIPTION; RHEUMATOID ARTHRITIS; RIB FRACTURE; RISK FACTOR; VITAMIN SUPPLEMENTATION; BACK PAIN; COMPLICATION; MEDICATION COMPLIANCE; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BACK PAIN; BONE DENSITY CONSERVATION AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; SPINAL FRACTURES; TERIPARATIDE; TREATMENT OUTCOME;

EID: 84893726334     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.05.001     Document Type: Article

References (34)

1. Lespessailles E., Cotte F.E., Roux C., et al. Prevalence and features of osteoporosis in the French general population: the Instant study. Joint Bone Spine 2009, 76:394-400.
2. Cawston H., Maravic M., Fardellone P., et al. Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. Arch Osteoporos 2012, 7:237-246.
3. Roux C., Fechtenbaum J., Kolta S., et al. Mild prevalent and incident vertebral fractures are risk factors for new fractures. Osteoporos Int 2007, 18:1617-1624.
4. Francis R.M., Aspray T.J., Hide G., et al. Back pain in osteoporotic vertebral fractures. Osteoporos Int 2008, 19:895-903.
5. Oglesby A.K., Minshall M.E., Shen W., et al. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. J Rheumatol 2003, 30:1579-1583.
6. Fechtenbaum J., Cropet C., Kolta S., et al. The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. Osteoporos Int 2005, 16:2175-2179.
7. Maravic M., Jouaneton B., Vainchtock A., et al. Economic burden of osteoporosis in women: data from the 2008 French hospital database (PMSI). Clin Exp Rheumatol 2012, 30:222-227.
8. Briot K., Cortet B., Thomas T., et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 2012, 79:304-313.
9. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 10:1434-1441.
10. Summary of product characteristics - Forsteo. EMA 2012 June 7 http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000425/human_med_000798.jsp.
11. Haute autorité de santé. Avis de la Commission: FORSTEO 20microgrammes/80microlitres, solution pour injection en stylo pré-rempli.
12. Avorn J. In defense of pharmacoepidemiology-embracing the yin and yang of drug research. N Engl J Med 2007, 357:2219-2221.
13. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996, 11:1215-1218.
14. Dowd R., Recker R.R., Heaney R.P. Study subjects and ordinary patients. Osteoporos Int 2000, 11:533-536.
15. Fahrleitner-Pammer A., Langdahl B.L., Marin F., et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 2011, 22:2709-2719.
16. Brooks R. EuroQol: the current state of play. Health Policy 1996, 37:53-72.
17. EuroQol Group EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990, 16:199-208.
18. Zeger S.L., Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121-130.
19. Rajzbaum G., Jakob F., Karras D., et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008, 24:377-384.
20. Aloumanis K., Karras D., Drossinos V., et al. Fracture incidence, quality of life, and back pain during 18-months treatment with teriparatide in Greek postmenopausal women with osteoporosis: results from the European Forsteo Observational Study. J Osteoporos 2011, 2011:510398.
21. Langdahl B.L., Rajzbaum G., Jakob F., et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009, 85:484-493.
22. Adachi J.D., Hanley D.A., Lorraine J.K., et al. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther 2007, 29:2055-2067.
23. Arden N.K., Earl S., Fisher D.J., et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 2006, 17:1626-1629.
24. Briot K., Ravaud P., Dargent-Molina P., et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 2009, 20:625-630.
25. Confavreux C.B., Canoui-Poitrine F., Schott A.M., et al. Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. Eur J Endocrinol 2012, 166:735-741.
26. Cramer J.A., Gold D.T., Silverman S.L., et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007, 18:1023-1031.
27. Lee S., Glendenning P., Inderjeeth C.A. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 2011, 22:741-753.
28. Yu S., Burge R.T., Foster S.A., et al. The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int 2012, 23:1103-1113.
29. Cotte F.E., De P.G. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv Res 2011, 11:151.
30. Prince R., Sipos A., Hossain A., et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005, 20:1507-1513.
31. Lindsay R., Scheele W.H., Neer R., et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004, 11:2024-2030.
32. Nevitt M.C., Chen P., Kiel D.P., et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 2006, 17:1630-1637.
33. Hadji P., Zanchetta J.R., Russo L., et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 2012, 23:2141-2150.
34. Roux C., Wyman A., Hooven F.H., et al. Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: The Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int 2012, 23:2863-2871.